CZ309217B6 - Lipidované peptidy jako neuroprotektiva - Google Patents

Lipidované peptidy jako neuroprotektiva Download PDF

Info

Publication number
CZ309217B6
CZ309217B6 CZ2014-364A CZ2014364A CZ309217B6 CZ 309217 B6 CZ309217 B6 CZ 309217B6 CZ 2014364 A CZ2014364 A CZ 2014364A CZ 309217 B6 CZ309217 B6 CZ 309217B6
Authority
CZ
Czechia
Prior art keywords
fatty acid
prrp20
prrp31
analogue
disease
Prior art date
Application number
CZ2014-364A
Other languages
English (en)
Other versions
CZ2014364A3 (cs
Inventor
Lenka Maletínská
Blanka Železná
Miroslava Blechová
Andrea Špolcová
Barbora Mikulášková
Original Assignee
Ústav organické chemie a biochemie AV ČR, v.v.i.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ústav organické chemie a biochemie AV ČR, v.v.i. filed Critical Ústav organické chemie a biochemie AV ČR, v.v.i.
Priority to CZ2014-364A priority Critical patent/CZ309217B6/cs
Priority to EP15729749.0A priority patent/EP3149029B1/en
Priority to US15/307,262 priority patent/US20170051031A1/en
Priority to CA2950416A priority patent/CA2950416C/en
Priority to PCT/CZ2015/000047 priority patent/WO2015180698A1/en
Priority to AU2015266464A priority patent/AU2015266464B2/en
Publication of CZ2014364A3 publication Critical patent/CZ2014364A3/cs
Priority to IL24837016A priority patent/IL248370B/en
Priority to US16/550,654 priority patent/US10751390B2/en
Publication of CZ309217B6 publication Critical patent/CZ309217B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Neuropeptidy PrRP31, PrRP20, obsahující C14 a C16 mastnou kyselinu a jejich analogy, jejichž C-koncová sekvence IRPVGRF-NH2 může být obměněna v místě fenalalaninu; mastná kyselina je v případě PrRP31 či jeho analogu navázána v poloze 1 nebo 11, u PrRP20 či jeho analogu v poloze 1 nebo 7; vazba zahrnuje amidovou vazbu mezi aminokyselinou, mající nejméně jednu volnou NH2 skupinu, a karboxylovou skupinou mastné kyseliny a alternativně zahrnuje i vazbu prostřednictvím raménka X-2, kterým je γ-glutamová kyselina, pro použití po periferním podání k léčbě a prevenci chorobných stavů, kterými jsou Alzheimerova choroba, Parkinsonova choroba, zhoršení kognice, které není demencí, mozkové trauma a neurodegenerativní změny a poruchy.
CZ2014-364A 2014-05-27 2014-05-27 Lipidované peptidy jako neuroprotektiva CZ309217B6 (cs)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CZ2014-364A CZ309217B6 (cs) 2014-05-27 2014-05-27 Lipidované peptidy jako neuroprotektiva
EP15729749.0A EP3149029B1 (en) 2014-05-27 2015-05-20 Lipidated peptides as neuroprotective agents
US15/307,262 US20170051031A1 (en) 2014-05-27 2015-05-20 Lipidated peptides as neuroprotective agents
CA2950416A CA2950416C (en) 2014-05-27 2015-05-20 Lipidated peptides as neuroprotective agents
PCT/CZ2015/000047 WO2015180698A1 (en) 2014-05-27 2015-05-20 Lipidated peptides as neuroprotective agents
AU2015266464A AU2015266464B2 (en) 2014-05-27 2015-05-20 Lipidated peptides as neuroprotective agents
IL24837016A IL248370B (en) 2014-05-27 2016-10-16 Covalently modified peptides with lipid extensions as neuroprotective components
US16/550,654 US10751390B2 (en) 2014-05-27 2019-08-26 Lipidated peptides as neuroprotective agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CZ2014-364A CZ309217B6 (cs) 2014-05-27 2014-05-27 Lipidované peptidy jako neuroprotektiva

Publications (2)

Publication Number Publication Date
CZ2014364A3 CZ2014364A3 (cs) 2015-12-16
CZ309217B6 true CZ309217B6 (cs) 2022-06-01

Family

ID=53432908

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2014-364A CZ309217B6 (cs) 2014-05-27 2014-05-27 Lipidované peptidy jako neuroprotektiva

Country Status (7)

Country Link
US (2) US20170051031A1 (cs)
EP (1) EP3149029B1 (cs)
AU (1) AU2015266464B2 (cs)
CA (1) CA2950416C (cs)
CZ (1) CZ309217B6 (cs)
IL (1) IL248370B (cs)
WO (1) WO2015180698A1 (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963296C (en) 2014-10-02 2021-01-05 Paul Scherrer Institut Human g protein alpha subunit g.alpha.i1 with at least one mutated amino acid residue
WO2023078478A1 (en) * 2021-11-08 2023-05-11 Ustav Organicke Chemie A Biochemie Av Cr, V. V. I. Lipidized cocaine- and amphetamine-regulated transcript peptide analogues as anti-obesity and neuroprotective agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024472A2 (en) * 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
WO2006030956A1 (ja) * 2004-09-15 2006-03-23 Takeda Pharmaceutical Company Limited ＰｒＲＰおよびその受容体の新規用途
CZ2012476A3 (cs) * 2012-07-12 2014-01-22 Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. Lipidované peptidy jako antiobezitika

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292132A1 (en) * 2007-09-11 2010-11-18 Dorian Bevec Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
DK2723363T3 (en) * 2011-06-24 2018-10-15 Nono Inc COMBINATION THERAPY AGAINST CREAM
JP6342016B2 (ja) 2014-01-15 2018-06-13 フィズィオロギッキ ウスタフ アカデミエ ヴェド ツェーエル，ヴェー．ヴェー．イー 血中グルコースを低下させるための、脂質付加されたペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024472A2 (en) * 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
WO2006030956A1 (ja) * 2004-09-15 2006-03-23 Takeda Pharmaceutical Company Limited ＰｒＲＰおよびその受容体の新規用途
CZ2012476A3 (cs) * 2012-07-12 2014-01-22 Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. Lipidované peptidy jako antiobezitika

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sun B et al. Blockade of PrRP attenuates MPTP-induced toxicity in mice. Peptides, 2009, 30(7),1267-75. *

Also Published As

Publication number Publication date
IL248370A0 (en) 2016-11-30
US20200016240A1 (en) 2020-01-16
EP3149029A1 (en) 2017-04-05
IL248370B (en) 2019-11-28
EP3149029B1 (en) 2019-06-19
CA2950416C (en) 2021-03-02
AU2015266464B2 (en) 2017-08-17
US20170051031A1 (en) 2017-02-23
AU2015266464A1 (en) 2016-10-27
US10751390B2 (en) 2020-08-25
CA2950416A1 (en) 2015-12-03
CZ2014364A3 (cs) 2015-12-16
WO2015180698A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
CL2018001395A1 (es) Composiciones farmacéuticas que comprenden amida de levodopa y sus uso
JOP20190147A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
NZ703341A (en) Compositions comprising apomorphine and organic acids and uses thereof
WO2016118014A3 (en) Anti-senescence compounds and uses thereof
IT201700087359A1 (it) Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2016000095A (es) Transtornos neurodegenerativos.
WO2016199076A3 (en) Polymorphic forms of afatinib free base and afatinib dimaleate
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
RU2017123388A (ru) Пептиды и их применение в уходе за кожей
WO2016170124A3 (en) Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
WO2018215525A8 (en) Mic-1 compounds and uses thereof
NI202000005A (es) Agentes, usos y métodos para el tratamiento
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
WO2014210544A3 (en) Adrenoceptors antagonists
CZ309217B6 (cs) Lipidované peptidy jako neuroprotektiva
PH12020552254A1 (en) Compositions comprising amino acids for use in the prevention and treatment of liver diseases
TWD199161S (zh) 牙齒矯正托架
EP3431460A3 (en) Novel formulation and method of synthesis
JP2015516943A5 (cs)
RU2016102092A (ru) Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений